Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03535090
Other study ID # IVMPCoagulation
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2011
Est. completion date December 31, 2014

Study information

Verified date May 2018
Source Medical University of Warsaw
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The alterations of coagulation and fibrinolysis parameters have been described in patients with endogenous Cushing's syndrome (CS) and those treated with glucocorticosteroids (GCs). The change in hemostatic process is associated with an increased risk of venous thromboembolic events (VTE) and pulmonary embolism (PE). Anticoagulation prophylaxis reduces thromboembolic complications in endogenous and exogenous hypercortisolism. The impact of the intravenous GCs therapy on hypercoagulability, however, remains unclear and perplexing. According to the European Group On Graves' Orbitopathy (EUGOGO), patients with active, severely symptomatic and sight-threatening Graves' orbitopathy (GO) should be treated with high dose intravenous methylprednisolone (IVMP) pulses. There are, however, reports of fatal side effects that may be associated with this therapy (e.g.: PE, myocardial infarction, severe cerebrovascular events, acute liver damage and sudden death). For this reason, the cumulative dose of IVMP should not exceed 8 g within each treatment course, and pulses should not be given on consecutive or alternate days, except for the case of dysthyroid optic neuropathy. Nevertheless, even smaller cumulative therapy may be associated with fatal cardiovascular complications. Hence the aim of our study was to evaluate the effects of IVMP therapy on hemostatic process in patients with GO. All of patients were treated according to EUGOGO recommendations with standard doses of methylprednisolone with standard recommended schedule. Inclusion criterion for the therapy was according to EUGOGO guidelines moderate-to-severe and active GO (12 pulses of IVMP 6x0.5g followed by 6x0.25g every week).


Description:

The end point of the study was a change in hemostatic variables' levels in laboratory tests. There were short- and long-term hemostatic changes analysed during IVMP therapy: comparisons of laboratory tests before, 24h and 48h after selected pulses, and between the beginning of 1st, 6th and 12th IVMP pulses, respectively. Hemostatic variables that were evaluated: factor [F] II, FV, FVII, FVIII, fibrinogen, antithrombin, activated partial thromboplastin time, prothrombin time, platelets and D - dimer. Moreover, analyses were performed concerning clinical data (such as age, sex, body mass index, smoking, duration time of GO, presence of hypertension, basal markers of thyroid function) between independent groups (patients with initially increased/reduced selected markers versus without increased/reduced selected markers).


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date December 31, 2014
Est. primary completion date December 31, 2014
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- active, moderate-to-severe Graves' orbitopathy according to EUGOGO classification

- euthyroidism for at least 1 month

- completion of at least first six IVMP pulses

Exclusion Criteria:

- medical history of thromboembolic events

- cardiovascular morbidity (chronic heart failure, cardiovascular heart disease)

- uncontrolled hypertension (systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg)

- liver disease (>3x increase of alanine aminotransferase and/or aspartate aminotransferase)

- active inflammation

- nephritic syndrome

- active neoplastic disease

- previous GCs therapy within the last 6 months

- trauma/surgery within the last 3 months

- pregnancy or a bedridden state

- use of: heparin, vitamin K antagonists, antiplatelet drugs, contraceptives or hormone replacement therapy

Study Design


Intervention

Drug:
Methylprednisolone


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Piotr Miskiewicz

Outcome

Type Measure Description Time frame Safety issue
Other Change in activity of coagulation factor VIII from baseline (before administration of methylprednisolone) to 48 hours after the first intravenous pulse 48 hours
Other Change of activated partial thromboplastin time (seconds) from baseline (before administration of methylprednisolone) to 48 hours after the first intravenous pulse 48 hours
Other Change in activity of coagulation factor VIII from baseline (before therapy) to the sixth pulse of the methylprednisolone 6 weeks
Other Change activated partial thromboplastin time (seconds) from baseline (before therapy) to the sixth pulse of the methylprednisolone 6 weeks
Primary Change in activity of coagulation factor VIII from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Primary Change in activity of coagulation factor VIII from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Primary Change in of activated partial thromboplastin time (seconds) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Primary Change in activated partial thromboplastin time (seconds) from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in activity of coagulation factor II from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in activity of coagulation factor V from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in activity of coagulation factor VII from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in prothrombin time (seconds) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in fibrinogen (mg/dl) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in D-Dimer (ng/dl) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in PLT count from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse 24 hours
Secondary Change in activity of coagulation factor II from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in activity of coagulation factor V from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in activity of coagulation factor VII from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in prothrombin time (seconds) from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in fibrinogen (mg/dl) from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in D-Dimer (ng/dl) from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
Secondary Change in PLT count from baseline (before therapy) to the end of the course of therapy with methylprednisolone 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05347550 - Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients N/A
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Completed NCT02379806 - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study Phase 3
Recruiting NCT03691753 - Safety and Efficacy Study of Fitaya Vena Cava Filter N/A
Completed NCT02197416 - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Phase 3
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT01895777 - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Phase 3
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Completed NCT04736420 - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Completed NCT04735523 - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736719 - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Completed NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Phase 2/Phase 3
Completed NCT02746185 - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban Phase 3
Completed NCT02912234 - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Phase 1
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Phase 2
Completed NCT02661568 - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) N/A
Completed NCT01972243 - Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
Completed NCT01976988 - Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery Phase 3